Proactiveinvestors Australia MaxCyte Inc https://www.proactiveinvestors.com.au Proactiveinvestors Australia MaxCyte Inc RSS feed en Sun, 09 Aug 2020 00:11:02 +1000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) Maxcyte: At the forefront of cell therapy revolution https://www.proactiveinvestors.com.au/companies/news/214111/maxcyte-at-the-forefront-of-cell-therapy-revolution-214111.html Wed, 15 Jul 2020 13:40:00 +1000 https://www.proactiveinvestors.com.au/companies/news/214111/maxcyte-at-the-forefront-of-cell-therapy-revolution-214111.html MaxCyte Inc 'demonstrating outstanding progress' as first half revenues climb 30% https://www.proactiveinvestors.com.au/companies/news/924260/maxcyte-inc--demonstrating-outstanding-progress--as-first-half-revenues-climb-30-924260.html Wed, 15 Jul 2020 10:43:00 +1000 https://www.proactiveinvestors.com.au/companies/news/924260/maxcyte-inc--demonstrating-outstanding-progress--as-first-half-revenues-climb-30-924260.html MaxCyte: Firing on all cylinders https://www.proactiveinvestors.com.au/companies/news/924256/maxcyte-firing-on-all-cylinders-924256.html Wed, 15 Jul 2020 10:35:00 +1000 https://www.proactiveinvestors.com.au/companies/news/924256/maxcyte-firing-on-all-cylinders-924256.html MaxCyte performs strongly in H1; CARMA Cell Therapies expected to be self-funding by year-end https://www.proactiveinvestors.com.au/companies/news/924235/maxcyte-performs-strongly-in-h1-carma-cell-therapies-expected-to-be-self-funding-by-year-end-924235.html Wed, 15 Jul 2020 08:55:00 +1000 https://www.proactiveinvestors.com.au/companies/news/924235/maxcyte-performs-strongly-in-h1-carma-cell-therapies-expected-to-be-self-funding-by-year-end-924235.html MaxCyte Inc - Proactive One2One Virtual Event https://www.proactiveinvestors.com.au/companies/news/923916/maxcyte-inc---proactive-one2one-virtual-event-923916.html Fri, 10 Jul 2020 06:41:00 +1000 https://www.proactiveinvestors.com.au/companies/news/923916/maxcyte-inc---proactive-one2one-virtual-event-923916.html MaxCyte: A win in gene silencing with APEIRON Biologics https://www.proactiveinvestors.com.au/companies/news/923702/maxcyte-a-win-in-gene-silencing-with-apeiron-biologics-923702.html Wed, 08 Jul 2020 10:19:00 +1000 https://www.proactiveinvestors.com.au/companies/news/923702/maxcyte-a-win-in-gene-silencing-with-apeiron-biologics-923702.html Maxcyte deal with APEIRON Biologics 'highlights value of its Flow Electroporation technology' https://www.proactiveinvestors.com.au/companies/news/923711/maxcyte-deal-with-apeiron-biologics--highlights-value-of-its-flow-electroporation-technology--923711.html Wed, 08 Jul 2020 09:49:00 +1000 https://www.proactiveinvestors.com.au/companies/news/923711/maxcyte-deal-with-apeiron-biologics--highlights-value-of-its-flow-electroporation-technology--923711.html MaxCyte signs clinical and commercial licensing deal APEIRON Biologics https://www.proactiveinvestors.com.au/companies/news/923676/maxcyte-signs-clinical-and-commercial-licensing-deal-apeiron-biologics-923676.html Wed, 08 Jul 2020 06:26:00 +1000 https://www.proactiveinvestors.com.au/companies/news/923676/maxcyte-signs-clinical-and-commercial-licensing-deal-apeiron-biologics-923676.html Maxcyte to present clinical data from MCY-M11 phase one trial at American Society of Clinical Oncology https://www.proactiveinvestors.com.au/companies/news/919559/maxcyte-to-present-clinical-data-from-mcy-m11-phase-one-trial-at-american-society-of-clinical-oncology-919559.html Thu, 14 May 2020 07:29:00 +1000 https://www.proactiveinvestors.com.au/companies/news/919559/maxcyte-to-present-clinical-data-from-mcy-m11-phase-one-trial-at-american-society-of-clinical-oncology-919559.html MaxCyte deal with Caribou 'demonstrates expertise and value' of its Flow Electroporation technology https://www.proactiveinvestors.com.au/companies/news/919265/maxcyte-deal-with-caribou--demonstrates-expertise-and-value--of-its-flow-electroporation-technology-919265.html Mon, 11 May 2020 12:10:00 +1000 https://www.proactiveinvestors.com.au/companies/news/919265/maxcyte-deal-with-caribou--demonstrates-expertise-and-value--of-its-flow-electroporation-technology-919265.html MaxCyte: Gold standard technology draws CRISPR pioneer Caribou https://www.proactiveinvestors.com.au/companies/news/919118/maxcyte-gold-standard-technology-draws-crispr-pioneer-caribou-919118.html Thu, 07 May 2020 14:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/919118/maxcyte-gold-standard-technology-draws-crispr-pioneer-caribou-919118.html MaxCyte agrees clinical and commercial deal with US t-cell therapy expert https://www.proactiveinvestors.com.au/companies/news/919035/maxcyte-agrees-clinical-and-commercial-deal-with-us-t-cell-therapy-expert-919035.html Thu, 07 May 2020 06:21:00 +1000 https://www.proactiveinvestors.com.au/companies/news/919035/maxcyte-agrees-clinical-and-commercial-deal-with-us-t-cell-therapy-expert-919035.html MaxCyte prepares for "new and exciting" growth chapter - and NASDAQ float - following £25mln fundraiser https://www.proactiveinvestors.com.au/companies/news/918600/maxcyte-prepares-for--new-and-exciting--growth-chapter---and-nasdaq-float---following-25mln-fundraiser-918600.html Fri, 01 May 2020 06:27:00 +1000 https://www.proactiveinvestors.com.au/companies/news/918600/maxcyte-prepares-for--new-and-exciting--growth-chapter---and-nasdaq-float---following-25mln-fundraiser-918600.html Maxcyte reports 30% revenue growth as key programmes advance through clinical studies https://www.proactiveinvestors.com.au/companies/news/918319/maxcyte-reports-30-revenue-growth-as-key-programmes-advance-through-clinical-studies-918319.html Tue, 28 Apr 2020 13:19:00 +1000 https://www.proactiveinvestors.com.au/companies/news/918319/maxcyte-reports-30-revenue-growth-as-key-programmes-advance-through-clinical-studies-918319.html MaxCyte: Milestones a key contributor to 30% top line growth https://www.proactiveinvestors.com.au/companies/news/918273/maxcyte-milestones-a-key-contributor-to-30-top-line-growth-918273.html Tue, 28 Apr 2020 09:47:00 +1000 https://www.proactiveinvestors.com.au/companies/news/918273/maxcyte-milestones-a-key-contributor-to-30-top-line-growth-918273.html MaxCyte confident after strong year; hails long-term momentum of the business https://www.proactiveinvestors.com.au/companies/news/917702/maxcyte-confident-after-strong-year-hails-long-term-momentum-of-the-business-917702.html Tue, 21 Apr 2020 06:45:00 +1000 https://www.proactiveinvestors.com.au/companies/news/917702/maxcyte-confident-after-strong-year-hails-long-term-momentum-of-the-business-917702.html MaxCyte still expecting growth in the life sciences business this year https://www.proactiveinvestors.com.au/companies/news/916995/maxcyte-still-expecting-growth-in-the-life-sciences-business-this-year-916995.html Thu, 09 Apr 2020 06:40:00 +1000 https://www.proactiveinvestors.com.au/companies/news/916995/maxcyte-still-expecting-growth-in-the-life-sciences-business-this-year-916995.html MaxCyte: Allogene deal is validation for new CAR-T wave https://www.proactiveinvestors.com.au/companies/news/915907/maxcyte-allogene-deal-is-validation-for-new-car-t-wave-915907.html Thu, 26 Mar 2020 15:16:00 +1100 https://www.proactiveinvestors.com.au/companies/news/915907/maxcyte-allogene-deal-is-validation-for-new-car-t-wave-915907.html Maxcyte deal with Allogene Therapeutics 'a clear endorsement' of its technology https://www.proactiveinvestors.com.au/companies/news/915903/maxcyte-deal-with-allogene-therapeutics--a-clear-endorsement--of-its-technology-915903.html Thu, 26 Mar 2020 10:21:00 +1100 https://www.proactiveinvestors.com.au/companies/news/915903/maxcyte-deal-with-allogene-therapeutics--a-clear-endorsement--of-its-technology-915903.html Proactive news snapshot: MaxCyte, Learning Technologies, Minds + Machines, Tekcapital … https://www.proactiveinvestors.com.au/companies/news/915636/proactive-news-snapshot-maxcyte-learning-technologies-minds--machines-tekcapital--915636.html Tue, 24 Mar 2020 15:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/915636/proactive-news-snapshot-maxcyte-learning-technologies-minds--machines-tekcapital--915636.html MaxCyte agrees licensing deal with next-generation CAR T pioneer https://www.proactiveinvestors.com.au/companies/news/915606/maxcyte-agrees-licensing-deal-with-next-generation-car-t-pioneer-915606.html Tue, 24 Mar 2020 12:22:00 +1100 https://www.proactiveinvestors.com.au/companies/news/915606/maxcyte-agrees-licensing-deal-with-next-generation-car-t-pioneer-915606.html MaxCyte in 'exceptional position to benefit from explosive growth in gene therapy' https://www.proactiveinvestors.com.au/companies/news/912160/maxcyte-in--exceptional-position-to-benefit-from-explosive-growth-in-gene-therapy--912160.html Tue, 04 Feb 2020 12:27:00 +1100 https://www.proactiveinvestors.com.au/companies/news/912160/maxcyte-in--exceptional-position-to-benefit-from-explosive-growth-in-gene-therapy--912160.html MaxCyte - delivering growth, highlighting value https://www.proactiveinvestors.com.au/companies/news/911660/maxcyte---delivering-growth-highlighting-value-911660.html Tue, 28 Jan 2020 12:58:00 +1100 https://www.proactiveinvestors.com.au/companies/news/911660/maxcyte---delivering-growth-highlighting-value-911660.html MaxCyte says outlook is "exceptionally positive" after stellar year https://www.proactiveinvestors.com.au/companies/news/910991/maxcyte-says-outlook-is--exceptionally-positive--after-stellar-year-910991.html Mon, 20 Jan 2020 11:01:00 +1100 https://www.proactiveinvestors.com.au/companies/news/910991/maxcyte-says-outlook-is--exceptionally-positive--after-stellar-year-910991.html MaxCyte appoints life-sciences vet as EVP, updates on lead therapy to treat solid tumors https://www.proactiveinvestors.com.au/companies/news/909686/maxcyte-appoints-life-sciences-vet-as-evp-updates-on-lead-therapy-to-treat-solid-tumors-909686.html Fri, 20 Dec 2019 18:04:00 +1100 https://www.proactiveinvestors.com.au/companies/news/909686/maxcyte-appoints-life-sciences-vet-as-evp-updates-on-lead-therapy-to-treat-solid-tumors-909686.html MaxCyte appoints new executive vice president as it continues trial of cancer drug https://www.proactiveinvestors.com.au/companies/news/909516/maxcyte-appoints-new-executive-vice-president-as-it-continues-trial-of-cancer-drug-909516.html Thu, 19 Dec 2019 09:06:00 +1100 https://www.proactiveinvestors.com.au/companies/news/909516/maxcyte-appoints-new-executive-vice-president-as-it-continues-trial-of-cancer-drug-909516.html MaxCyte offering exposure to 'explosive growth' in cell therapy and cellular engineering https://www.proactiveinvestors.com.au/companies/news/908578/maxcyte-offering-exposure-to--explosive-growth--in-cell-therapy-and-cellular-engineering-908578.html Thu, 05 Dec 2019 13:25:00 +1100 https://www.proactiveinvestors.com.au/companies/news/908578/maxcyte-offering-exposure-to--explosive-growth--in-cell-therapy-and-cellular-engineering-908578.html Proactive news snapshot: MaxCyte, IXICO, Eurasia Mining, VR Education, Advanced Oncotherapy … https://www.proactiveinvestors.com.au/companies/news/908439/proactive-news-snapshot-maxcyte-ixico-eurasia-mining-vr-education-advanced-oncotherapy--908439.html Wed, 04 Dec 2019 15:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/908439/proactive-news-snapshot-maxcyte-ixico-eurasia-mining-vr-education-advanced-oncotherapy--908439.html MaxCyte inks new development and commercialization agreement with KSQ Therapeutics https://www.proactiveinvestors.com.au/companies/news/908437/maxcyte-inks-new-development-and-commercialization-agreement-with-ksq-therapeutics-908437.html Wed, 04 Dec 2019 09:15:00 +1100 https://www.proactiveinvestors.com.au/companies/news/908437/maxcyte-inks-new-development-and-commercialization-agreement-with-ksq-therapeutics-908437.html MaxCyte - Pole Position in Cell and Gene Therapy https://www.proactiveinvestors.com.au/companies/news/907893/maxcyte---pole-position-in-cell-and-gene-therapy-907893.html Tue, 26 Nov 2019 15:36:00 +1100 https://www.proactiveinvestors.com.au/companies/news/907893/maxcyte---pole-position-in-cell-and-gene-therapy-907893.html MaxCyte inks licensing deal with cutting-edge US cancer drug developer https://www.proactiveinvestors.com.au/companies/news/907528/maxcyte-inks-licensing-deal-with-cutting-edge-us-cancer-drug-developer-907528.html Thu, 21 Nov 2019 08:02:00 +1100 https://www.proactiveinvestors.com.au/companies/news/907528/maxcyte-inks-licensing-deal-with-cutting-edge-us-cancer-drug-developer-907528.html MaxCyte increases dose level for mesothelioma and ovarian cancer patients in its Phase I trials https://www.proactiveinvestors.com.au/companies/news/905581/maxcyte-increases-dose-level-for-mesothelioma-and-ovarian-cancer-patients-in-its-phase-i-trials-905581.html Thu, 24 Oct 2019 14:33:00 +1100 https://www.proactiveinvestors.com.au/companies/news/905581/maxcyte-increases-dose-level-for-mesothelioma-and-ovarian-cancer-patients-in-its-phase-i-trials-905581.html Maxcyte licenses cell engineering technology to Nasdaq-listed Editas https://www.proactiveinvestors.com.au/companies/news/904253/maxcyte-licenses-cell-engineering-technology-to-nasdaq-listed-editas-904253.html Mon, 07 Oct 2019 07:49:00 +1100 https://www.proactiveinvestors.com.au/companies/news/904253/maxcyte-licenses-cell-engineering-technology-to-nasdaq-listed-editas-904253.html MaxCyte to make five presentations before the year-end on groundbreaking CARMA system https://www.proactiveinvestors.com.au/companies/news/903711/maxcyte-to-make-five-presentations-before-the-year-end-on-groundbreaking-carma-system-903711.html Mon, 30 Sep 2019 06:27:00 +1000 https://www.proactiveinvestors.com.au/companies/news/903711/maxcyte-to-make-five-presentations-before-the-year-end-on-groundbreaking-carma-system-903711.html Maxcyte keen to broaden reach of cancer drug platform Carma https://www.proactiveinvestors.com.au/companies/news/902950/maxcyte-keen-to-broaden-reach-of-cancer-drug-platform-carma-902950.html Wed, 18 Sep 2019 10:57:00 +1000 https://www.proactiveinvestors.com.au/companies/news/902950/maxcyte-keen-to-broaden-reach-of-cancer-drug-platform-carma-902950.html MaxCyte making "significant progress" commercially and in the clinic https://www.proactiveinvestors.com.au/companies/news/224033/maxcyte-making--significant-progress--commercially-and-in-the-clinic-224033.html Wed, 17 Jul 2019 06:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/224033/maxcyte-making--significant-progress--commercially-and-in-the-clinic-224033.html MaxCyte starts dosing second cohort of patients in early-stage trial of its lead cancer drug https://www.proactiveinvestors.com.au/companies/news/219844/maxcyte-starts-dosing-second-cohort-of-patients-in-early-stage-trial-of-its-lead-cancer-drug-219844.html Wed, 08 May 2019 06:25:00 +1000 https://www.proactiveinvestors.com.au/companies/news/219844/maxcyte-starts-dosing-second-cohort-of-patients-in-early-stage-trial-of-its-lead-cancer-drug-219844.html MaxCyte shows off CARMA platform at industry conference in Washington DC https://www.proactiveinvestors.com.au/companies/news/219444/maxcyte-shows-off-carma-platform-at-industry-conference-in-washington-dc-219444.html Wed, 01 May 2019 06:57:00 +1000 https://www.proactiveinvestors.com.au/companies/news/219444/maxcyte-shows-off-carma-platform-at-industry-conference-in-washington-dc-219444.html MaxCyte looks ahead to “pivotal” 2019 with demand for its cell engineering platform on the rise https://www.proactiveinvestors.com.au/companies/news/219004/maxcyte-looks-ahead-to-pivotal-2019-with-demand-for-its-cell-engineering-platform-on-the-rise-219004.html Wed, 24 Apr 2019 06:42:00 +1000 https://www.proactiveinvestors.com.au/companies/news/219004/maxcyte-looks-ahead-to-pivotal-2019-with-demand-for-its-cell-engineering-platform-on-the-rise-219004.html Healthcheck on cell therapy group MaxCyte https://www.proactiveinvestors.com.au/companies/news/313076/healthcheck-on-cell-therapy-group-maxcyte-13076.html Tue, 23 Apr 2019 14:50:00 +1000 https://www.proactiveinvestors.com.au/companies/news/313076/healthcheck-on-cell-therapy-group-maxcyte-13076.html MaxCyte launches latest iteration of its Flow Electroporation cell editing technology https://www.proactiveinvestors.com.au/companies/news/218113/maxcyte-launches-latest-iteration-of-its-flow-electroporation-cell-editing-technology-218113.html Mon, 08 Apr 2019 06:26:00 +1000 https://www.proactiveinvestors.com.au/companies/news/218113/maxcyte-launches-latest-iteration-of-its-flow-electroporation-cell-editing-technology-218113.html MaxCyte extends relationship with Gilead Sciences-owned cancer drug developer Kite https://www.proactiveinvestors.com.au/companies/news/215587/maxcyte-extends-relationship-with-gilead-sciences-owned-cancer-drug-developer-kite-215587.html Fri, 01 Mar 2019 07:31:00 +1100 https://www.proactiveinvestors.com.au/companies/news/215587/maxcyte-extends-relationship-with-gilead-sciences-owned-cancer-drug-developer-kite-215587.html MaxCyte raises £10mln to extend its CARMA platform into a second trial https://www.proactiveinvestors.com.au/companies/news/312198/maxcyte-raises-10mln-to-extend-its-carma-platform-into-a-second-trial-12198.html Wed, 13 Feb 2019 01:09:00 +1100 https://www.proactiveinvestors.com.au/companies/news/312198/maxcyte-raises-10mln-to-extend-its-carma-platform-into-a-second-trial-12198.html MaxCyte raises £10mln in share placing to accelerate growth strategy https://www.proactiveinvestors.com.au/companies/news/213955/maxcyte-raises-10mln-in-share-placing-to-accelerate-growth-strategy-213955.html Tue, 05 Feb 2019 17:00:00 +1100 https://www.proactiveinvestors.com.au/companies/news/213955/maxcyte-raises-10mln-in-share-placing-to-accelerate-growth-strategy-213955.html MaxCyte says earnings likely to beat expectations after bumper end to the year https://www.proactiveinvestors.com.au/companies/news/212562/maxcyte-says-earnings-likely-to-beat-expectations-after-bumper-end-to-the-year-212562.html Tue, 15 Jan 2019 07:36:00 +1100 https://www.proactiveinvestors.com.au/companies/news/212562/maxcyte-says-earnings-likely-to-beat-expectations-after-bumper-end-to-the-year-212562.html MaxCyte updates on plans to simplify share structure https://www.proactiveinvestors.com.au/companies/news/209647/maxcyte-updates-on-plans-to-simplify-share-structure-209647.html Wed, 21 Nov 2018 07:38:00 +1100 https://www.proactiveinvestors.com.au/companies/news/209647/maxcyte-updates-on-plans-to-simplify-share-structure-209647.html MaxCyte teams up with American gene editing specialist to develop new generation of cancer treatments https://www.proactiveinvestors.com.au/companies/news/209151/maxcyte-teams-up-with-american-gene-editing-specialist-to-develop-new-generation-of-cancer-treatments-209151.html Wed, 14 Nov 2018 07:34:00 +1100 https://www.proactiveinvestors.com.au/companies/news/209151/maxcyte-teams-up-with-american-gene-editing-specialist-to-develop-new-generation-of-cancer-treatments-209151.html Major announcements for MaxCyte https://www.proactiveinvestors.com.au/companies/news/311185/major-announcements-for-maxcyte-11185.html Tue, 13 Nov 2018 11:38:00 +1100 https://www.proactiveinvestors.com.au/companies/news/311185/major-announcements-for-maxcyte-11185.html MaxCyte inks research agreement with Gilead subsidiary Kite Pharma https://www.proactiveinvestors.com.au/companies/news/208981/maxcyte-inks-research-agreement-with-gilead-subsidiary-kite-pharma-208981.html Mon, 12 Nov 2018 07:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/208981/maxcyte-inks-research-agreement-with-gilead-subsidiary-kite-pharma-208981.html CRISPR Therapeutics to use MaxCyte’s technology in its search for cancer gene therapies https://www.proactiveinvestors.com.au/companies/news/208897/crispr-therapeutics-to-use-maxcytes-technology-in-its-search-for-cancer-gene-therapies-208897.html Fri, 09 Nov 2018 07:41:00 +1100 https://www.proactiveinvestors.com.au/companies/news/208897/crispr-therapeutics-to-use-maxcytes-technology-in-its-search-for-cancer-gene-therapies-208897.html MaxCyte doses first ovarian cancer patient in phase 1 clinical trial https://www.proactiveinvestors.com.au/companies/news/310889/maxcyte-doses-first-ovarian-cancer-patient-in-phase-1-clinical-trial-10889.html Wed, 17 Oct 2018 17:52:00 +1100 https://www.proactiveinvestors.com.au/companies/news/310889/maxcyte-doses-first-ovarian-cancer-patient-in-phase-1-clinical-trial-10889.html MaxCyte doses first phase I patient https://www.proactiveinvestors.com.au/companies/news/206749/maxcyte-doses-first-phase-i-patient-206749.html Wed, 10 Oct 2018 06:50:00 +1100 https://www.proactiveinvestors.com.au/companies/news/206749/maxcyte-doses-first-phase-i-patient-206749.html MaxCyte on track to start first-ever clinical trial before the end of the year https://www.proactiveinvestors.com.au/companies/news/205512/maxcyte-on-track-to-start-first-ever-clinical-trial-before-the-end-of-the-year-205512.html Mon, 24 Sep 2018 07:15:00 +1000 https://www.proactiveinvestors.com.au/companies/news/205512/maxcyte-on-track-to-start-first-ever-clinical-trial-before-the-end-of-the-year-205512.html CAR-T therapies: All you wanted to know and were too afraid to ask https://www.proactiveinvestors.com.au/companies/news/204261/car-t-therapies-all-you-wanted-to-know-and-were-too-afraid-to-ask-204261.html Wed, 05 Sep 2018 14:34:00 +1000 https://www.proactiveinvestors.com.au/companies/news/204261/car-t-therapies-all-you-wanted-to-know-and-were-too-afraid-to-ask-204261.html MaxCyte gears up for first clinical trial after gaining regulatory green light https://www.proactiveinvestors.com.au/companies/news/200817/maxcyte-gears-up-for-first-clinical-trial-after-gaining-regulatory-green-light-200817.html Mon, 16 Jul 2018 11:04:00 +1000 https://www.proactiveinvestors.com.au/companies/news/200817/maxcyte-gears-up-for-first-clinical-trial-after-gaining-regulatory-green-light-200817.html MaxCyte hails US National Institutes of Health tie-up to find treatment for sickle cell disease https://www.proactiveinvestors.com.au/companies/news/198577/maxcyte-hails-us-national-institutes-of-health-tie-up-to-find-treatment-for-sickle-cell-disease-198577.html Mon, 11 Jun 2018 08:05:00 +1000 https://www.proactiveinvestors.com.au/companies/news/198577/maxcyte-hails-us-national-institutes-of-health-tie-up-to-find-treatment-for-sickle-cell-disease-198577.html MaxCyte pre-clinical data shows correction of sickle cell disease mutation https://www.proactiveinvestors.com.au/companies/news/197343/maxcyte-pre-clinical-data-shows-correction-of-sickle-cell-disease-mutation-197343.html Mon, 21 May 2018 06:33:00 +1000 https://www.proactiveinvestors.com.au/companies/news/197343/maxcyte-pre-clinical-data-shows-correction-of-sickle-cell-disease-mutation-197343.html MaxCyte appoints Infinity Pharma's Claudio Dansky Ullmann as its chief medical officer https://www.proactiveinvestors.com.au/companies/news/195733/maxcyte-appoints-infinity-pharma-s-claudio-dansky-ullmann-as-its-chief-medical-officer-195733.html Wed, 25 Apr 2018 08:47:00 +1000 https://www.proactiveinvestors.com.au/companies/news/195733/maxcyte-appoints-infinity-pharma-s-claudio-dansky-ullmann-as-its-chief-medical-officer-195733.html MaxCyte defying the odds as it gears up for pivotal year https://www.proactiveinvestors.com.au/companies/news/191636/maxcyte-defying-the-odds-as-it-gears-up-for-pivotal-year-191636.html Wed, 04 Apr 2018 12:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/191636/maxcyte-defying-the-odds-as-it-gears-up-for-pivotal-year-191636.html MaxCyte reports strong growth in cash and total assets in 2017 as revenues increase by 14% https://www.proactiveinvestors.com.au/companies/news/194227/maxcyte-reports-strong-growth-in-cash-and-total-assets-in-2017-as-revenues-increase-by-14-194227.html Wed, 04 Apr 2018 07:19:00 +1000 https://www.proactiveinvestors.com.au/companies/news/194227/maxcyte-reports-strong-growth-in-cash-and-total-assets-in-2017-as-revenues-increase-by-14-194227.html MaxCyte appoints biotech pioneer as independent director https://www.proactiveinvestors.com.au/companies/news/191559/maxcyte-appoints-biotech-pioneer-as-independent-director-191559.html Tue, 13 Feb 2018 08:04:00 +1100 https://www.proactiveinvestors.com.au/companies/news/191559/maxcyte-appoints-biotech-pioneer-as-independent-director-191559.html MaxCyte Inc gearing up for phase I study of potential cancer breakthrough https://www.proactiveinvestors.com.au/companies/news/308650/maxcyte-inc-gearing-up-for-phase-i-study-of-potential-cancer-breakthrough-8650.html Tue, 23 Jan 2018 11:53:00 +1100 https://www.proactiveinvestors.com.au/companies/news/308650/maxcyte-inc-gearing-up-for-phase-i-study-of-potential-cancer-breakthrough-8650.html MaxCyte prepares for phase I study of potential cancer breakthrough; says trading in line with market expectations https://www.proactiveinvestors.com.au/companies/news/190359/maxcyte-prepares-for-phase-i-study-of-potential-cancer-breakthrough-says-trading-in-line-with-market-expectations-190359.html Mon, 22 Jan 2018 15:03:00 +1100 https://www.proactiveinvestors.com.au/companies/news/190359/maxcyte-prepares-for-phase-i-study-of-potential-cancer-breakthrough-says-trading-in-line-with-market-expectations-190359.html MaxCyte making progress; primed and ready for further advance https://www.proactiveinvestors.com.au/companies/news/184197/maxcyte-making-progress-primed-and-ready-for-further-advance-184197.html Tue, 19 Sep 2017 07:06:00 +1000 https://www.proactiveinvestors.com.au/companies/news/184197/maxcyte-making-progress-primed-and-ready-for-further-advance-184197.html ‘More of the same, please’: MaxCyte poised for continued growth after solid first half https://www.proactiveinvestors.com.au/companies/news/172131/more-of-the-same-please-maxcyte-poised-for-continued-growth-after-solid-first-half-172131.html Wed, 12 Jul 2017 13:35:00 +1000 https://www.proactiveinvestors.com.au/companies/news/172131/more-of-the-same-please-maxcyte-poised-for-continued-growth-after-solid-first-half-172131.html MaxCyte poised for more growth after progress across all areas of the business this year https://www.proactiveinvestors.com.au/companies/news/180744/maxcyte-poised-for-more-growth-after-progress-across-all-areas-of-the-business-this-year-180744.html Wed, 12 Jul 2017 06:42:00 +1000 https://www.proactiveinvestors.com.au/companies/news/180744/maxcyte-poised-for-more-growth-after-progress-across-all-areas-of-the-business-this-year-180744.html MaxCyte's Doug Doerfler 'confident of providing long-term treatment' for CGD patients https://www.proactiveinvestors.com.au/companies/news/307588/maxcyte-s-doug-doerfler-confident-of-providing-long-term-treatment-for-cgd-patients-7588.html Tue, 06 Jun 2017 14:25:00 +1000 https://www.proactiveinvestors.com.au/companies/news/307588/maxcyte-s-doug-doerfler-confident-of-providing-long-term-treatment-for-cgd-patients-7588.html MaxCyte to collaborate with leading infectious disease institute once again https://www.proactiveinvestors.com.au/companies/news/178837/maxcyte-to-collaborate-with-leading-infectious-disease-institute-once-again-178837.html Tue, 06 Jun 2017 08:02:00 +1000 https://www.proactiveinvestors.com.au/companies/news/178837/maxcyte-to-collaborate-with-leading-infectious-disease-institute-once-again-178837.html Doug Doerfler on the 'incredibly exciting' opportunities ahead for Maxcyte https://www.proactiveinvestors.com.au/companies/news/307538/doug-doerfler-on-the-incredibly-exciting-opportunities-ahead-for-maxcyte-7538.html Fri, 26 May 2017 11:19:00 +1000 https://www.proactiveinvestors.com.au/companies/news/307538/doug-doerfler-on-the-incredibly-exciting-opportunities-ahead-for-maxcyte-7538.html Maxcyte to publish positive data from Sickle Cell treatment reasearch https://www.proactiveinvestors.com.au/companies/news/176837/maxcyte-to-publish-positive-data-from-sickle-cell-treatment-reasearch-176837.html Tue, 25 Apr 2017 07:28:00 +1000 https://www.proactiveinvestors.com.au/companies/news/176837/maxcyte-to-publish-positive-data-from-sickle-cell-treatment-reasearch-176837.html Drug developer MaxCyte unveils plans to raise £20mln to accelerate the development of its technology https://www.proactiveinvestors.com.au/companies/news/175731/drug-developer-maxcyte-unveils-plans-to-raise-20mln-to-accelerate-the-development-of-its-technology-175731.html Fri, 31 Mar 2017 06:27:00 +1100 https://www.proactiveinvestors.com.au/companies/news/175731/drug-developer-maxcyte-unveils-plans-to-raise-20mln-to-accelerate-the-development-of-its-technology-175731.html Cell science MaxCyte annual results reveal a period of significant progress https://www.proactiveinvestors.com.au/companies/news/175047/cell-science-maxcyte-annual-results-reveal-a-period-of-significant-progress-175047.html Mon, 20 Mar 2017 14:50:00 +1100 https://www.proactiveinvestors.com.au/companies/news/175047/cell-science-maxcyte-annual-results-reveal-a-period-of-significant-progress-175047.html MaxCyte boss Doerfler excited by gene-editing licence deal https://www.proactiveinvestors.com.au/companies/news/307102/maxcyte-boss-doerfler-excited-by-gene-editing-licence-deal-7102.html Tue, 14 Mar 2017 16:21:00 +1100 https://www.proactiveinvestors.com.au/companies/news/307102/maxcyte-boss-doerfler-excited-by-gene-editing-licence-deal-7102.html MaxCyte deal puts it at the forefront of developments in the cutting edge arena of gene editing https://www.proactiveinvestors.com.au/companies/news/174753/maxcyte-deal-puts-it-at-the-forefront-of-developments-in-the-cutting-edge-arena-of-gene-editing-174753.html Tue, 14 Mar 2017 08:21:00 +1100 https://www.proactiveinvestors.com.au/companies/news/174753/maxcyte-deal-puts-it-at-the-forefront-of-developments-in-the-cutting-edge-arena-of-gene-editing-174753.html MaxCyte hails potential of its CARMA platform after "strong" pre-clinical test results https://www.proactiveinvestors.com.au/companies/news/174110/maxcyte-hails-potential-of-its-carma-platform-after-strong-pre-clinical-test-results-174110.html Thu, 02 Mar 2017 10:15:00 +1100 https://www.proactiveinvestors.com.au/companies/news/174110/maxcyte-hails-potential-of-its-carma-platform-after-strong-pre-clinical-test-results-174110.html MaxCyte revenues grow 30%; on track to beat City forecasts https://www.proactiveinvestors.com.au/companies/news/172077/maxcyte-revenues-grow-30-on-track-to-beat-city-forecasts-172077.html Tue, 24 Jan 2017 07:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/172077/maxcyte-revenues-grow-30-on-track-to-beat-city-forecasts-172077.html MaxCyte study results point to the effectiveness of its technology https://www.proactiveinvestors.com.au/companies/news/171520/maxcyte-study-results-point-to-the-effectiveness-of-its-technology-171520.html Thu, 12 Jan 2017 07:59:00 +1100 https://www.proactiveinvestors.com.au/companies/news/171520/maxcyte-study-results-point-to-the-effectiveness-of-its-technology-171520.html MaxCyte joins the battle to combat acute myeloid leukemia https://www.proactiveinvestors.com.au/companies/news/170778/maxcyte-joins-the-battle-to-combat-acute-myeloid-leukemia-170778.html Wed, 21 Dec 2016 15:25:00 +1100 https://www.proactiveinvestors.com.au/companies/news/170778/maxcyte-joins-the-battle-to-combat-acute-myeloid-leukemia-170778.html MaxCyte's latest deal 'a perfect relationship' says CEO Doug Doerfler https://www.proactiveinvestors.com.au/companies/news/306645/maxcyte-s-latest-deal-a-perfect-relationship-says-ceo-doug-doerfler-6645.html Wed, 21 Dec 2016 14:25:00 +1100 https://www.proactiveinvestors.com.au/companies/news/306645/maxcyte-s-latest-deal-a-perfect-relationship-says-ceo-doug-doerfler-6645.html Maxcyte revenues climb as big pharma seeks next generation of drugs https://www.proactiveinvestors.com.au/companies/news/166523/maxcyte-revenues-climb-as-big-pharma-seeks-next-generation-of-drugs-166523.html Tue, 27 Sep 2016 07:44:00 +1000 https://www.proactiveinvestors.com.au/companies/news/166523/maxcyte-revenues-climb-as-big-pharma-seeks-next-generation-of-drugs-166523.html MaxCyte hires Asian distributors to meet demand https://www.proactiveinvestors.com.au/companies/news/156634/maxcyte-hires-asian-distributors-to-meet-demand-156634.html Tue, 06 Sep 2016 07:47:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156634/maxcyte-hires-asian-distributors-to-meet-demand-156634.html MaxCyte driving CARMA forwards https://www.proactiveinvestors.com.au/companies/news/305278/maxcyte-driving-carma-forwards-5278.html Wed, 13 Jul 2016 13:56:00 +1000 https://www.proactiveinvestors.com.au/companies/news/305278/maxcyte-driving-carma-forwards-5278.html MaxCyte shares rise 4% after upbeat update https://www.proactiveinvestors.com.au/companies/news/128087/maxcyte-shares-rise-4-after-upbeat-update-128087.html Tue, 12 Jul 2016 10:31:00 +1000 https://www.proactiveinvestors.com.au/companies/news/128087/maxcyte-shares-rise-4-after-upbeat-update-128087.html MaxCyte chief says potential of breakthrough technology CARMA should not be underestimated https://www.proactiveinvestors.com.au/companies/news/305015/maxcyte-chief-says-potential-of-breakthrough-technology-carma-should-not-be-underestimated-5015.html Wed, 11 May 2016 12:36:00 +1000 https://www.proactiveinvestors.com.au/companies/news/305015/maxcyte-chief-says-potential-of-breakthrough-technology-carma-should-not-be-underestimated-5015.html MaxCyte delivering on its hybrid strategy https://www.proactiveinvestors.com.au/companies/news/125720/maxcyte-delivering-on-its-hybrid-strategy-125720.html Tue, 10 May 2016 13:08:00 +1000 https://www.proactiveinvestors.com.au/companies/news/125720/maxcyte-delivering-on-its-hybrid-strategy-125720.html MaxCyte's hybrid model will appeal to UK investors https://www.proactiveinvestors.com.au/companies/news/125434/maxcyte-s-hybrid-model-will-appeal-to-uk-investors-125434.html Mon, 02 May 2016 06:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/125434/maxcyte-s-hybrid-model-will-appeal-to-uk-investors-125434.html MaxCyte lists on AIM to develop cancer treatments https://www.proactiveinvestors.com.au/companies/news/124130/maxcyte-lists-on-aim-to-develop-cancer-treatments-124130.html Tue, 29 Mar 2016 07:25:00 +1100 https://www.proactiveinvestors.com.au/companies/news/124130/maxcyte-lists-on-aim-to-develop-cancer-treatments-124130.html